- Home
- TROO vs HLVX Comparison
TROO vs HLVX Comparison
Compare TROO & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TROO
- HLVX
- Stock Information
- Founded
- TROO 2005
- HLVX 2020
- Country
- TROO Hong Kong
- HLVX United States
- Employees
- TROO N/A
- HLVX N/A
- Industry
- TROO Radio And Television Broadcasting And Communications Equipment
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- TROO Technology
- HLVX Health Care
- Exchange
- TROO Nasdaq
- HLVX Nasdaq
- Market Cap
- TROO 103.8M
- HLVX 104.3M
- IPO Year
- TROO N/A
- HLVX 2022
- Fundamental
- Price
- TROO $1.04
- HLVX $2.10
- Analyst Decision
- TROO
- HLVX Hold
- Analyst Count
- TROO 0
- HLVX 1
- Target Price
- TROO N/A
- HLVX $2.00
- AVG Volume (30 Days)
- TROO 214.3K
- HLVX 647.7K
- Earning Date
- TROO 09-03-2025
- HLVX 11-06-2025
- Dividend Yield
- TROO N/A
- HLVX N/A
- EPS Growth
- TROO N/A
- HLVX N/A
- EPS
- TROO N/A
- HLVX N/A
- Revenue
- TROO $10,073,000.00
- HLVX N/A
- Revenue This Year
- TROO N/A
- HLVX N/A
- Revenue Next Year
- TROO N/A
- HLVX N/A
- P/E Ratio
- TROO N/A
- HLVX N/A
- Revenue Growth
- TROO 182.24
- HLVX N/A
- 52 Week Low
- TROO $0.49
- HLVX $1.34
- 52 Week High
- TROO $4.64
- HLVX $2.17
- Technical
- Relative Strength Index (RSI)
- TROO 58.49
- HLVX 52.75
- Support Level
- TROO $0.92
- HLVX $2.07
- Resistance Level
- TROO $1.09
- HLVX $2.11
- Average True Range (ATR)
- TROO 0.10
- HLVX 0.03
- MACD
- TROO -0.00
- HLVX 0.00
- Stochastic Oscillator
- TROO 62.82
- HLVX 46.67
About TROO TROOPS Inc.
TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.